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0.89); p  <  0.001]. The highest Youden index was observed for 
a TDI score <25 (Youden index: 0.58). Using this cutoff score 
and that generated from normative data of healthy controls, 
the TDI score provided high sensitivity (negative predictive 
value) and specificity (positive predictive value) of approxi-
mately 80% for detecting PD.  Conclusion: Olfactory testing 
is a useful, easily applied and inexpensive diagnostic test 
which is helpful to detect PD among tremor patients. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Discrimination of tremor-dominant Parkinson’s dis-
ease (PD) from other tremor disorders such as essential 
tremor (ET) is often difficult, particularly in the early dis-
ease stages with occasional monosymptomatic tremor in 
PD. Olfactory dysfunction is a characteristic and early fea-
ture of PD with more than 95% of subjects presenting with 
a significant loss of olfactory function independently of the 
subtype of the disease and thus including the tremor-dom-
inant form of PD  [1–5] . Olfactory testing is used in the 
diagnosis of PD  [2, 6, 7] ; however, its value in the differen-
 Key Words 
 Olfactory testing · Tremor · Parkinson’s disease · Essential 
tremor 
 Abstract 
 Background/Aims: The diagnostic value of olfactory testing 
for the discrimination of tremor-dominant Parkinson’s dis-
ease (PD) from other tremor disorders remains enigmatic. 
We evaluated whether olfactory testing can accurately de-
tect PD in tremor patients.  Methods: A retrospective analysis 
of 299 consecutive subjects referred for the differential diag-
nosis of a tremor disorder was done. Olfactory testing was 
performed using ‘Sniffin’ Sticks’, resulting in a composite TDI 
score of odor threshold (T), discrimination (D), and identifica-
tion (I). Receiver operating curve (ROC) plots were used to 
calculate sensitivity/specificity for the detection of PD.  Re-
sults: Of all subjects, 167 (55.9%) had PD and 85 (28.4%) had 
essential tremor (ET). The mean TDI score in PD was signifi-
cantly reduced compared to those in ET and other tremor 
disorders with no differences between ET and other tremor 
disorders. ROC analysis revealed strong correlations of TDI 
scores with PD [area under the curve: 0.85 (95% CI: 0.80–
 Received: August 27, 2013 
 Accepted: December 15, 2013 
 Published online: April 26, 2014 
 Alexander Storch, MD 
 Division of Neurodegenerative Diseases, Department of Neurology 
 Dresden University of Technology, Fetscherstrasse 74 
 DE–01307 Dresden (Germany) 
 E-Mail alexander.storch   @   neuro.med.tu-dresden.de 
 © 2014 S. Karger AG, Basel
0014–3022/14/0722–0001$39.50/0 
 www.karger.com/ene 
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:0
7:
31
 A
M
 Wolz  /Hähner  /Meixner  /Löhle  /
Reichmann  /Hummel  /Storch  
 
Eur Neurol 2014;72:1–6 
DOI: 10.1159/000358054
2
tial diagnosis between tremor-dominant PD and other 
tremor disorders remains unclear. In contrast to patients 
with various forms of parkinsonism, subjects suffering 
from most tremor disorders other than PD do not experi-
ence an impairment of olfactory function at all or less se-
vere hyposmia compared to PD patients  [7–10] . Shah et al. 
 [8]  performed odor identification testing using the Uni-
versity of Pennsylvania Smell Identification Test (UPSIT) 
in ET compared to tremor-dominant PD. They reported 
high sensitivity and specificity of the standard cutoff values 
to distinguish PD from ET patients, but no other quantita-
tive measures of the discriminatory power or the opti-
mized cutoff values of UPSIT, e.g. by using the receiver 
operating curve (ROC) analysis; no diagnostic predictive 
values were reported, which would be important for diag-
nostic purposes. The aim of this study was thus to investi-
gate the diagnostic accuracy of psychophysical olfactory 
testing in differentiating PD from other tremor disorders.
 Materials and Methods 
 Study Population 
 In this single-center retrospective study, we analyzed data of 
302 consecutive subjects admitted to the Department of Neurol-
ogy for a differential diagnosis of a tremor syndrome and who un-
derwent olfactory testing between September 2004 and October 
2009. Final diagnoses were established using available diagnostic 
criteria for PD  [11] , ET  [12] , and other tremor syndromes  [12] . 
Patients not fulfilling these diagnostic criteria (n = 88; 29.4%) un-
derwent functional brain imaging using standard  18 F-dopa posi-
tron emission tomography or DAT-SCAN single-photon emission 
computed tomography. The study was approved by the Institu-
tional Review Board at the Dresden University of Technology.
 Olfactory Testing 
 Olfactory testing was performed using the ‘Sniffin’ Sticks’ test 
kit  [13, 14] which involves tests for odor threshold (T), odor dis-
crimination (D), and odor identification (I). Odor identification 
was assessed for 16 common odors (orange, leather, cinnamon, 
menthol, banana, lemon, licorice, garlic, coffee, apple, pineapple, 
rose, fish, anise, clove, and turpentine) using a multiple forced-
choice design, namely subjects identify odors by selecting the best 
label from a list of 4 descriptors. Results of the 3 subtests are pre-
sented as a composite TDI score (range: 1–48), which is the sum 
of the results obtained for threshold (range: 1–16), discrimination 
(range: 0–16), and identification (range: 0–16) measures  [14] .
 Statistical Analyses 
 We assessed the performance of specific cutoff points for olfac-
tion test measures to detect PD using specificity and sensitivity, 
positive and negative predictive values (PPV and NPV) according 
to the Bayes’ theorem, and the likelihood ratio. ROC plots includ-
ing calculation of the area under the curve (AUC) were used to 
display sensitivity and specificity of olfactory testing measures for 
the detection of PD. For the generation of cutoff values from ROC 
analysis, we used the Youden index as a measure of the theoretical 
optimum of test scores. Results are presented as mean ± SD and 
range, as mean with 95% confidence interval (95% CI) in paren-
theses, or as number with percentage in parentheses. Variables 
were compared by one-way ANOVA/ANCOVA with Bonferroni-
adjusted post hoc t tests or the χ 2 test as appropriate. Statistical 
significance was defined for all analyses as p < 0.05. Statistical tests 
were performed using SPSS 19.0 (SPSS, Chicago, Ill., USA).
 Results 
 Study Cohort 
 The characteristics of the study cohort are shown in 
 table 1 . Of a total of 302 tremor subjects, 299 subjects were 
included in the analysis (3 subjects were excluded due to 
incomplete olfactory testing). 167 (55.9%) subjects were 
diagnosed with PD, 85 (28.4%) with ET and 47 (15.7%) 
with other tremor disorders [enhanced physiological 
tremor in 5 (1.7%), neuropathic tremor in 5 (1.7%), mul-
tiple system atrophy (MSA) in 5 (1.7%), cerebellar tremor 
in 2 (0.7%), psychogenic tremor in 2 (0.7%), dystonic 
tremor in 2 (0.7%), various tremor syndromes in 3 (1.0%), 
and unclassified tremor in 23 (7.7%) subjects].
 Olfactory Testing 
 All subscores and items of the olfactory testing were 
completed by 299 out of 302 subjects (99%). There were 
no adverse events during olfactory testing.  Table 1 sum-
marizes the data of the olfactory testing. The mean TDI 
score in the PD group was significantly reduced com-
pared to those in the ET and the other tremor disorder 
groups, but no differences in TDI scores were observed 
between the ET group and the other tremor disorder 
groups. For the subgroup of patients with MSA as a synu-
cleinopathy such as PD, the mean ± SD TDI score of 20.5 
± 10.5 (range: 7.0–32.5) was similar to that of PD (p = 
0.644) but significantly lower compared to that of ET sub-
jects (p < 0.001). Similar results were obtained for the sub-
scores of threshold, discrimination, and identification. 
The TDI scores correlated with age in the PD and ET 
groups with no differences between all subject groups 
[linear TDI decline per year of age was –0.160 (p < 0.001; 
95% CI: –0.234 to –0.086) in PD, –0.185 (p < 0.001; 95% 
CI: –0.282 to –0.089) in ET, and –0.197 (p = 0.101; 95% 
CI: –0.434 to 0.040) in other tremor disorders]. One-way 
ANCOVA with age as covariate confirmed that the mean 
TDI scores were significantly different between the sub-
ject groups (p < 0.001; F value: 103.4). Similar results were 
observed for the subscores. The TDI score and its sub-
scores did not correlate with sex in all subject groups.
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 ROC analyses revealing sensitivities and specificities 
of any particular cutoff value of the TDI score and all 
three subscores to detect PD in tremor disorders are 
shown in  figure 1 . The intervals between cutoff values for 
the TDI score were between 7 (90th percentile specificity) 
and 28 (90th percentile sensitivity). The same intervals 
for the threshold subscore were between 2 and 7, for the 
discrimination subscore between 7 and 12, and for the 
identification subscore between 9 and 12. The highest 
Youden index was observed for the TDI score <25 
(Youden index: 0.58), for the threshold subscore <4 
(0.34), for the discrimination subscore <10 (0.40), and for 
the identification subscore <11 (0.60). The sensitivity/
specificity values obtained at the maximal Youden index 
were slightly higher for the TDI score (by using both the 
cutoffs from normative data from healthy controls and 
the cutoffs generated by the ROC analysis) and for the 
identification subscore than for the threshold and the dis-
crimination subscores ( table 2 ). Hence, cutoff points of 
24 for the TDI score (meaning that a score of 24 or less 
indicates PD, whereas 25 or more indicates non-PD trem-
or) and 3 for the threshold score, 9 for the discrimination 
score, and 10 for the identification score were used to 
compare the utility of the tests for the diagnosis of PD in 
tremor subjects. 
 The ROC analyses indicated that the identification 
subscore had a similar discriminatory power (AUC of 
ROC) compared to the TDI compound score, but a high-
er discriminative power (higher AUC of ROC) compared 
to the other subscores ( fig. 1 ). ROC analyses for the sub-
sample of subjects with PD or ET only excluding the oth-
er tremor disorder subjects revealed similar results and 
 Table 1.  Demographic and clinical data
Total PD ET Others p value
Patients, n 299 167 85 47
Females, n (%) 110 (36.4) 51 (30.5) 41 (48.2) 18 (38.3) 0.022a
Age, years 64.0 ± 10.9 (18 – 87) 63.9 ± 10.2 (36 – 85) 63.4 ± 13.0 (18 – 87) 65.6 ± 8.6 (43 – 81) 0.526b
Olfactory testing
TDI, points – 19.0 ± 6.7 (1.0 – 34.5) 30.5 ± 4.9 (15.5 – 42.0) 24.2 ± 7.0 (3.0 – 34.0) <0.001b
Threshold, points – 3.3 ± 2.2 (1.0 – 10.5) 5.7 ± 2.2 (1.0 – 12.0) 3.9 ± 2.4 (1.0 – 11.3) <0.001b
Discrimination, points – 8.1 ± 2.9 (0 – 15) 11.7 ± 2.2 (6 – 16) 9.4 ± 3.2 (0 – 15) <0.001b
Identification, points – 7.7 ± 3.3 (0 – 16) 13.1 ± 2.0 (7 – 16) 10.9 ± 3.1 (2 – 15) <0.001b
 Values for age and olfactory testing are given as means ± SD with the range in parentheses.
a Pearson’s χ2 test: subsequent Pearson’s χ2 tests for individual group comparisons revealed significant differences only between ET 
and PD (p = 0.006). 
b One-way ANOVA: post hoc t test with Bonferroni adjustment revealed statistical differences with p < 0.05 between all groups, ex-
cept for the comparison of thresholds between PD and other tremor disorders (p = 0.231).
 Table 2.  Comparison of the utility of TDI, threshold, discrimination, and identification for the detection of PD in tremor syndromes
TDI 
(cutoff: normative data 
from healthy controls)a
TDI 
(cutoff from ROC 
analysis: 25)b
Threshold 
(cutoff from ROC 
analysis: 4)b
Discrimination 
(cutoff from ROC
analysis: 10)b
Identification 
(cutoff from ROC 
analysis: 11)b
Sensitivity (95% CI) 62.3% (54.4 – 69.6) 76.0% (69.5 – 82.5) 68.3% (61.2 – 75.4) 65.3% (58.1 – 72.5) 79.0% (72.8 – 85.2)
Specificity (95% CI) 88.6% (83.2 – 94.0) 78.8% (71.8 – 85.8) 65.9% (57.8 – 74.0) 72.0% (64.5 – 79.7) 80.3% (73.5 – 87.1)
PPVc (95% CI) 87.4% (80.0 – 92.5) 81.9% (74.8 – 87.5) 71.7% (63.9 – 78.4) 74.7% (66.7 – 81.3) 83.5% (76.6 – 88.8)
NPVc  (95% CI) 65.0% (57.5 – 71.9) 77.2% (68.0 – 82.6) 62.1% (53.5 – 70.1) 62.1% (53.9 – 69.8) 75.2% (67.1 – 81.9)
Likelihood ratio 5.5 3.6 2.0 2.3 4.0
 a The age-related cutoff values from age-adjusted normative data by Hummel et al. [14] were 24.9 (<15 years of age), 30.3 (16–35 years of age), 27.3 
(36–55 years of age), and 19.6 (>55 years of age). 
b The cutoff values from ROC analysis at the highest Youden index were used for calculations. 
c Calculated using the Bayes’ theorem.
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the same cutoffs for the TDI score and all subscores for 
discriminating PD from ET (data not shown). 
 Reducing the combination of identification scores 
from 16 odors in the original test battery down to the 8 
(cinnamon, menthol, banana, licorice, apple, pineapple, 
anise, and fish) or 4 (banana, licorice, pineapple, and an-
ise), odor identification scores using the odors with the 
best performance (highest AUC in ROC) led to similar 
discriminatory power as the full 16-odor identification 
score (AUC for the 8-odor score: 0.86 (95% CI: 0.82–
0.91), p < 0.0001; AUC for the 4-odor score: 0.84 (95% CI: 
0.79–0.88), p < 0.0001).
 Utility of Olfactory Testing to Discriminate PD from 
Other Tremor Syndromes 
 Table 2 compares the utility of the TDI score and its 
subscores to detect PD in subjects with tremor by apply-
ing the cutoff scores from ROC analyses using the Youden 
index and for TDI scores using the cutoffs generated from 
age-adjusted normative data of a healthy control sample 
 [14] . Using these cutoff scores, the TDI score and the 
identification subscore provided high sensitivity (NPV) 
and specificity (PPV) of approximately 80% for detecting 
PD in a cohort of consecutive tremor subjects. Similar 
results were obtained for the detection of PD in the sub-
cohort of subjects with ET excluding the other tremor 
disorders (data not shown).
 Discussion 
 The present study shows sufficient diagnostic validity 
for psychophysical olfactory testing to diagnose PD in 
tremor disorder subjects with high PPV and NPV of ap-
proximately 80% independently of tremor subtype, age, 
or gender. In agreement with previous reports  [1, 2, 8] , 
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 Fig. 1. ROC curves displaying the sensitiv-
ity and specificity of TDI ( a ), threshold ( b ), 
discrimination ( c ) and identification ( d ) 
for diagnosis of PD within the overall trem-
or population.  
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we observed significantly lower olfactory function in sub-
jects with PD compared to those with ET and other trem-
or disorders  [2, 8] , but we did not detect any differences 
in age dependency between PD, ET, and other tremor dis-
orders. As in a previous report  [15] , olfactory function in 
MSA as a synucleinopathy sometimes resembling PD in 
the first disease stages was similar to that in PD. Our data 
clearly support the view that inexpensive olfactory testing 
may constitute a suitable diagnostic instrument for de-
tecting PD in subjects with tremor syndromes indepen-
dently of age, gender and tremor subtype.
 External validity measured by ROC analysis using the 
available diagnostic criteria combined with functional 
brain imaging in unclear cases as the external validation 
criterion indicated that both the composite TDI score and 
the identification subscore have sufficient discriminatory 
power as a diagnostic tool for detecting PD in tremor dis-
orders. Applying the standard age-related cutoff values 
for the TDI score generated from normative data of a 
healthy cohort  [14] , the TDI score had high specificity 
(PPV) but only modest sensitivity (NPV) for the detec-
tion of PD. The optimal cutoff for the TDI score as as-
sessed by ROC analysis using the Youden index in our 
study was 24, leading to high values for specificity (PPV) 
and sensitivity (NPV). Interestingly, using a single odor 
identification test with 16 or even less odors also seems to 
have sufficient discriminatory validity for detecting PD in 
tremor subjects.
 The comparison between the diagnostic accuracy of 
olfactory testing and previously reported data on DAT-
SCAN single-photon emission computed tomography 
imaging  [16] suggests that functional brain imaging is as-
sociated with higher diagnostic validity for the detection 
of PD in tremor disorders (sensitivity for the clinical di-
agnosis of parkinsonism of 97% and specificity for ET of 
100%). However, olfactory testing is an easy and inexpen-
sive technique which might be available at each Move-
ment Disorder Center. In contrast to functional brain im-
aging, no adverse events are expected and no administra-
tion of radioactive compounds is required  [16] .
 Our study has some limitations. We performed a ret-
rospective study in tremor subjects who were seen con-
secutively. Hence, only a limited clinical dataset was 
available (e.g. no data on disease onset or duration were 
available), and the diagnosis in the majority of cases was 
made using standard clinical diagnostic criteria with lim-
ited diagnostic accuracy  [11, 12] . The diagnosis was con-
firmed with functional imaging in only 29% of subjects. 
Another point of criticism could be the fact that data 
were only obtained in a single university-based study 
center with a potential bias in patient referral. On the 
other hand, since we calculated our data in a consecutive 
tremor subject cohort, the presented diagnostic accuracy 
data apply for tremor patients independently of demo-
graphic characteristics and tremor subtype and thus ap-
ply for tremor patients at their first diagnostic consulta-
tion.
 In conclusion, this study demonstrates that olfactory 
testing is a valid and useful instrument in detecting PD in 
tremor disorders. It has sufficient sensitivity and specific-
ity with an age-independent cutoff point for the TDI 
score of <25, which is independent of demographic pa-
rameters. The external validity ranked highly as indicated 
by the ROC analysis. TDI and odor identification scores 
were related to the absence or presence of PD in tremor 
subjects. In comparison to most other tools for this diag-
nostic problem, olfactory testing has the advantages of 
being very brief, inexpensive, and easy. In a stepwise di-
agnostic approach, olfactory testing should thus be used 
as a first diagnostic test prior to more laborious and ex-
pensive tests such as functional brain imaging.
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